ERBB2 and breast cancer: HER2-positive breast cancers with a high CTCFL mRNA expression have a trend towards worse OS compared with counterparts with low CTCFL mRNA expression (HR = 1.67, 95% CI = 0.96–2.89, p = 0.065, Figure 7c).